China: Artic Vision closes Series B round at US$100m

Pipeline of Arctic Vision by March 2021

Arctic Vision, a China-based clinical-stage ophthalmology company, has completed its Series B financing at more than US$100m. The round was led by Loyal Valley Capital, with participation from Tencent, Octagon Capital, and Adrian Cheng, an entrepreneur from New World Development Group, along with existing investors Nan Fung Life Sciences, Pivotal bioVenture Partners China and Morningside…

You must be a HMI Subscriber to view this content.

Subscribe Now »